Pimavanserin responders in Alzheimer's psychosis also see benefit in agitation, aggression

Patients with Alzheimer's disease whose psychotic symptoms improved with use of pimavanserin also showed improvement in agitation and aggression compared with nonresponders to the treatment, a study has found. These differences on agitation and aggression also were apparent in patients with higher baseline levels of these symptoms, the researchers reported.